Live Breaking News & Updates on Yescarta

Stay updated with breaking news from Yescarta. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Gene Therapy, DNA's Past, RNA's Future: A New Wave Of Hope

Over the last ten years, we have witnessed a transformation from speculative science to a reality where genetic disorders are treated not just in theory but in reality. ....

Terry Horgan , Jesse Gelsinger , European Union , New Wave , Gene Therapy Trials , Gene Therapy , Regenerative Medicine ,

Tumor Characteristics Predict Improved CAR-T Cell Therapy Outcomes

Certain tumor characteristics were predictive of which patients with lymphoma may have better outcomes with the CAR-T cell therapy, Yescarta. ....

Frederickl Locke , Cellular Immunotherapy Department At Moffitt Cancer Center , Drug Administration , Marrow Transplant , Moffitt Cancer Center , Largeb Cell Lymphoma , Cart Cell Therapy ,

Axi-Cel Provides Sustained Response in High-Risk Large B-cell Lymphoma

Patients with high-risk large B-cell lymphoma experienced durable responses when treated with first-line axicabtagene ciloleucel, according to results from the phase 2 ZUMA-12 trial. ....

Julio Chavez , Lymphoma Section , Malignant Hematology , Moffitt Cancer Center , Axi Cel , Zuma 12 Trial , High Risk Largeb Cell Lymphoma , Ash Annual Meeting ,

Axi-Cel Improves Overall Survival vs Standard-of-Care Initial Treatment for R/R LBCL

A prespecified overall survival analysis of the phase 3 ZUMA-7 trial found that axicabtagene ciloleucel (axi-cel) led to better outcomes vs the historical standard of care for relapsed or refractory large B-cell lymphoma (R/R LBCL). ....

Kite Pharma , Special Protocol Assessment , Axi Cel , Axicabtagene Ciloleucel , Zuma 7 ,